$MDCO News

Last published 5y ago

5y agoNVS MDCOAttralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New ExecutivesBusiness WireAttralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field Attralus Therapeutics today announced the appointment o
6y agoMDCOBlade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the BoardBusiness WireSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, a leader in the fields of fibrosis, COVID-19 pathogenesis and inflammatory biology, today announced the appointment of Mark Timney as Chairman of the Board of Directors. Mr. Timney succeeds Luke Evnin, Ph.D., co-founder and Managing Director of MPM, who has served as Chairman since the founding of Blade Therapeutics in 2015. Dr. Evn ...
6y agoMDCOThe Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3.50% Convertible Senior Notes due 2024 (the “2024 Notes,” and collectively with the 2022 Notes and 2023 Notes, the ...
6y agoCLVS CNSP SRNE MDCO+1How FDA and Oncology Industry are Making Joint Efforts to Utilize Accelerated Approval Pathways for Cancer DrugsPR NewswireWorldwide, cancer drug sales bring in the most revenues for pharmaceutical companies. Worldwide cancer drug sales are already way ahead of those of...
6y agoMDCONovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathGlobeNewswireOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
6y agoMDCOThe Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 BillionBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion. The price represents a premium of approximately 45% to The Medicines Company’s closing share price of $58.65 ...
6y agoMDCOThe Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly DosingBusiness WirePHILADELPHIA--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-9, the last of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class. In ...
6y agoMDCOThe Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly DosingBusiness WirePHILADELPHIA--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class. ...
7y agoMDCOThe Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association (AHA) Scientific Sessions 2019, November 16-18, in Philadelphia. The Company will also be hosting and sponsoring educational ...
7y agoMDCOThe Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for InclisiranBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today reported financial results for the third quarter that ended September 30, 2019. Third-quarter highlights included successful completion of pivotal Phase 3 LDL cholesterol (LDL-C) lowering clinical trials for inclisiran with presentation of efficacy and safety data for ORION-11 at the European Society of Cardiology’s ESC ...
7y agoMDCOThe Medicines Company to Announce Third Quarter 2019 Financial Results on October 30Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, October 30, 2019 at 8:30 a.m. EDT to discuss its third quarter 2019 financial results and operational developments.
7y agoMDCOThe Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines ConferenceBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a “fireside chat” discussion at 8:00 a.m. Eastern Daylight Time.
7y agoMDCOThe Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD PatientsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-10 Phase 3 clinical study in patients with atherosclerotic cardiovascular disease (ASCVD), successfully completing the pivotal Phase 3 LDL-cholesterol (LDL-C) lowering clinical trials for inclisiran. ORION-10 met all primary and secondary endpoints, and inclisiran demonstr ...
7y agoMDCOThe Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia PatientsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced positive topline results for the ORION-9 Phase 3 clinical study in patients with Heterozygous Familial Hypercholesterolemia (HeFH). ORION-9 met all primary and secondary endpoints, and inclisiran demonstrated durable and potent efficacy and was well-tolerated with excellent safety that was generally well-balanc ...
7y agoMDCOThe Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly DosingBusiness WirePARIS--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol (LDL-C) and the first and only cholesterol-lowering therapy in the siRNA (small-interfering RNA or “sir-nah”) class. In ORION-11, twice-ye ...
7y agoMDCOThe Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of InclisiranBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced positive topline results from the first pivotal Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing. The ORION-11 study of inclisiran sodium 300 mg met all primary and secondary endpoints with efficacy consistent ...
7y agoMDCOThe Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development ProgramBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today reported financial results for the second quarter that ended June 30, 2019. Second quarter highlights included significant progress with the clinical development program for inclisiran and the completion of a public offering of common stock.
7y agoMDCOThe Medicines Company to Announce Second Quarter 2019 Financial Results on July 24Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments.
7y agoMDCOThe Medicines Company Announces Pricing of Public Offering of Common StockBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share. Gross proceeds of the offering are expected to be approximately $150 million, before underwriting discounts and commissions and other transaction expenses. In addition, the und ...
7y agoMDCOThe Medicines Company Announces Launch of Public Offering of Common StockBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the underwriters will be granted a 30-day option to purchase from the Company up to an additional $22.5 million of shares of common stock. The Company expects to use the net proceeds of the offering to f ...
7y agoMDCOThe Medicines Company (MDCO) CEO Mark Timney on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoMDCOThe Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2018.
7y agoMDCOThe Medicines Company Announces Upcoming Investor Conference PresentationsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced today that management will present company overviews at the following conferences:
7y agoMDCOThe Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.m. EST to discuss its fourth-quarter and full-year 2018 financial results and operational developments.
7y agoMDCOThe Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 TrialsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the 5th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed. The IDMC has once again recommended that the trials continue as designed and conducted, without modification.
7y agoMDCOThe Medicines Company Prices $150 Million of Convertible NotesBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024. The notes will be sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be senior unsecured obli ...
7y agoMDCOThe Medicines Company Announces Intention to Offer $150 Million of Convertible NotesBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. T ...
7y agoMDCOThe Medicines Company Appoints Mark Timney as Chief Executive OfficerBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company’s new Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the Board to serve as Chief Innovation Officer.
8y agoMDCOCompany Profile for The Medicines CompanyBusiness Wire--(BUSINESS WIRE)--The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care.
8y agoMDCOThe Medicines Company Reports Third-Quarter 2018 ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today reported its financial results for the third quarter ended September 30, 2018.
8y agoMDCOThe Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.m., EST, to discuss its third-quarter 2018 financial results and operational developments.
8y agoMDCOThe Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded DataBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification. The IDMC’s recommendation was based on its planned review of unblinded safety and efficacy data from the trials.
8y agoMDCOThe Medicines Company (MDCO) CEO Clive Meanwell on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoMDCOThe Medicines Company Reports Second-Quarter 2018 ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.
8y agoMDCOThe Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT to discuss its second-quarter 2018 financial results and operational developments.
8y agoMDCOThe Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded DataBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification. The IDMC’s recommendation was based on its planned review of unblinded safety and efficacy data from the trials.
8y agoMDCONew Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with DiabetesBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando (ADA 2018).
8y agoMDCOThe Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and StrokeBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86th European Atherosclerosis Society Congress (EAS 2018) and accepted for publication in Circulation, the journal of the American Heart Association.
8y agoMDCOThe Medicines Company Presents New Data at the National Lipid Association Scientific SessionsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV. Multiple studies in the ORION development program demonstrate that the proposed dosing regimen is likely to be the same for a wide range of dyslipide ...
8y agoMDCOThe Medicines Company Reports First-Quarter 2018 ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018.
8y agoMDCOThe Medicines Company to Announce First-Quarter 2018 Financial Results on April 25Business WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments.
8y agoMDCOThe Medicines Company Announces Chief Financial Officer TransitionBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli succeeds William B. O’Connor, who is retiring from the Company after serving as Chief Accounting Officer and then Chief Financial Officer for a total of 13 years. Mr. O’Connor will ...
8y agoMDCOThe Medicines Company to Participate in the Oppenheimer 28th Annual Healthcare ConferenceBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY. The Company is scheduled to present at 08:00 a.m., Eastern Time.
8y agoMDCOThe Medicines Company Reaches Enrollment Target for ORION-10 Ahead of ScheduleBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that randomization of more than 1,500 patients in the ORION-10 trial in the United States has been completed in only 12 weeks – considerably beating its goal of 22 weeks. ORION-10 is a double-blind, randomized Phase III trial designed to confirm the efficacy and safety of inclisiran, an investigational agent wh ...
8y agoMDCOThe Medicines Company to Participate in the Cowen 38th Annual Health Care ConferenceBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Cowen 38th Annual Health Care Conference on Tuesday, March 13, 2018, in Boston, MA. The Company is scheduled to present at 10:00 a.m., Eastern Time.
8y agoMDCOThe Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of DirectorsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately.
8y agoMDCOThe Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2017.
8y agoMDCOThe Medicines Company Reaches Enrollment Target for ORION-9 Ahead of ScheduleBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks – considerably ahead of its anticipated recruitment goal of 24 weeks.
8y agoMDCOThe Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial ResultsBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2017 financial results and operational developments.
8y agoMDCOThe Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare ConferenceBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City. Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a fireside chat at 9:00 a.m., Eastern Time.